Key facts
- It has raised $4.0M; the latest was Early Stage VC ($4.0M) in Jun 2025.
- Notable investors include BioGenerator Ventures, Missouri Technology Corporation, Bayer (Conglomerates), Plaisance Capital Management, St. Louis County Economic Council.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Aferna
- ·The full record, as it builds
Funding rounds
No funding rounds for Aferna are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aferna
Developer of molecular tools designed to expand the potential of biology to help plants grow healthier. The company develops ribonucleic acid-based molecular tools to create beneficial crop traits by working in partnership with nature, enabling agriculture to produce more robust crops and contribute to environmental well-being.
- Sector
- Business Products and Services (B2B)
- HQ
- Saint Louis, MO, United States
- Employees
- 11
- Website
- afernabio.com/
- Ownership
- Privately Held (backing)
Aferna doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aferna shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aferna in its N-PORT filings yet. We sweep new filings monthly.